Research

Expanding our footprint in advancing precision medicine for children with malignant brain tumors, we are funding Dr. Samuel H. Cheshier, MD, PhD, to lead an innovative precision medicine program at Intermountain Primary Children’s Hospital that tailors treatment to each child’s unique brain tumor. Over the past four years, this approach has already been applied successfully to [...]

Dr. Eric Raabe of Johns Hopkins University is leading innovative research to tackle ATRT by addressing one of its root causes: faulty gene control that keeps tumor cells locked in an immature, aggressive state. This preclinical project tests a promising new drug called corin, which targets a key epigenetic protein complex that ATRT cells rely [...]

Embryonal tumor with multilayered rosettes (ETMR) is one of the rarest and most aggressive brain tumors affecting very young children, and relapse is heartbreakingly common. Dr. Johannes Gojo of the Medical University of Vienna is leading a forward-thinking research project to understand why ETMR tumors return and how resistant cancer cells manage to survive treatment. [...]

Atypical teratoid/rhabdoid tumors (ATRT) are rare, aggressive brain tumors that primarily affect very young children and have limited treatment options. Dr. Rajeev Vibhakar at the Children's Hospital of Colorado is leading research to investigate a promising new approach by targeting a critical protein—called CDK7—that ATRT tumor cells depend on to grow and survive. By blocking [...]